What joules are recommended for synchronized electrical cardioversion of a hemodynamically stable adult with supraventricular tachycardia refractory to vagal maneuvers and medication?

Cardioversion Energy for Supraventricular Tachycardia

For hemodynamically stable SVT refractory to vagal maneuvers and medication, synchronized cardioversion should be performed starting at 50–100 J using a biphasic defibrillator. 1

Initial Energy Selection

• Start with 50–100 J synchronized for stable SVT when pharmacologic therapy has failed or is contraindicated. 1
• This energy range achieves near-100% termination of both AVNRT and AVRT. 1
• Use synchronized mode—never unsynchronized shocks—because SVT has organized QRS complexes that allow the device to time the shock appropriately. 1

Energy Escalation Protocol

• If the initial 50–100 J shock fails to convert the rhythm, increase energy in a stepwise fashion for subsequent attempts. 1
• The specific increments (e.g., 100 J → 150 J → 200 J) represent expert consensus, as no definitive studies have established optimal escalation steps. 1

Critical Pre-Cardioversion Checklist

Confirm Hemodynamic Stability

• Proceed immediately to cardioversion without sedation if the patient exhibits hypotension, altered mental status, shock, chest pain, or acute heart failure—these signs define instability and mandate urgent intervention. 1
• In truly stable patients (normal blood pressure, alert, no chest pain or pulmonary edema), provide appropriate sedation or anesthesia before the procedure. 1

Verify the Rhythm

• Obtain a 12-lead ECG during tachycardia to confirm SVT and exclude ventricular tachycardia or pre-excited atrial fibrillation (Wolff-Parkinson-White). 1
• If the rhythm is wide-complex or uncertain, manage as ventricular tachycardia (starting at 100 J synchronized) until proven otherwise. 1, 2
• Never use synchronized cardioversion for ventricular fibrillation or pulseless VT, as the device may fail to sense a QRS and deliver no shock. 3

Exclude Pre-Excitation

• If pre-excitation (delta waves) is present on the baseline ECG and the patient develops atrial fibrillation, do not cardiovert with low energy—use higher energy or pharmacologic therapy (procainamide or ibutilide) instead, because AV-nodal blockade can precipitate ventricular fibrillation. 1

Post-Cardioversion Management

• Maintain continuous cardiac monitoring for at least 1–2 hours after successful conversion, because premature atrial or ventricular complexes frequently trigger recurrent SVT within seconds to minutes. 1, 4
• If immediate recurrence occurs, administer a longer-acting AV-nodal blocker (oral diltiazem or a β-blocker) to prevent re-initiation. 1, 4
• Check serum electrolytes (potassium, magnesium) and correct abnormalities, as hypokalemia and hypomagnesemia predispose to arrhythmias. 1

Common Pitfalls to Avoid

• Do not delay cardioversion in unstable patients to attempt additional pharmacologic therapy—hypotension with tachycardia constitutes a medical emergency. 1
• Do not use unsynchronized shocks for SVT—this is reserved for ventricular fibrillation and pulseless VT only. 3
• Do not assume the patient is stable solely because oxygen saturation is preserved; assess blood pressure, mental status, and perfusion. 1
• Do not omit sedation in stable patients—appropriate anesthesia improves patient comfort and procedural success. 1

Long-Term Considerations

• After successful cardioversion, refer the patient to cardiology or electrophysiology for consideration of catheter ablation (94–98% single-procedure success) or long-term pharmacologic prophylaxis if episodes are recurrent. 1, 5
• Catheter ablation is the most effective, safe, and cost-effective approach for preventing recurrent SVT and should be offered as first-line definitive therapy. 1, 5